Opioid-Induced Opsoclonus-Myoclonus Syndrome Treatment

Introduction to Opsoclonus-Myoclonus

The American Society of Clinical Oncology notes that opsoclonus-mioclonus is a manifestation of opioid-induced neurotoxicity, characterized by rapid, multidirectional, and involuntary eye movements (opsoclonus) and brief, involuntary muscle jerks (myoclonus) 1
The European Society for Medical Oncology states that this condition represents a symptom of central nervous system toxicity that can occur during opioid use, especially when there is an accumulation of toxic metabolites 2
The symptoms often present alongside other signs of neurotoxicity such as delirium, hallucinations, cognitive impairment, and hyperalgesia, as reported by the European Society for Medical Oncology 2

The American College of Clinical Pharmacology recommends evaluating renal function, as most opioids are primarily eliminated through the kidneys and the accumulation of metabolites can contribute to delirium and neurotoxicity 1
The European Society of Anaesthesiology suggests reviewing the history of rapid opioid dose escalation, which is a risk factor for the development of neurotoxicity 1
The American Society of Clinical Oncology advises considering rotation to another opioid with a different chemical structure as the most effective strategy for managing symptoms of neurotoxicity such as opsoclonus-mioclonus 2

The American Pain Society recommends reducing the dose of the current opioid if rotation is not immediately possible 2
The European Society for Medical Oncology suggests considering fentanyl as an alternative, as it does not have active metabolites and may be preferable in cases of renal insufficiency 3, 2
The American College of Clinical Pharmacology advises eliminating other medications that may contribute to neurotoxicity when possible 1

The American Society of Clinical Oncology recommends avoiding rapid opioid dose escalation 1
The European Society of Intensive Care Medicine suggests monitoring patients with risk factors such as renal or hepatic insufficiency closely 3
The American College of Clinical Pharmacology advises considering the use of synthetic opioids (such as fentanyl) instead of natural opiates (such as morphine and codeine) in patients with a history of adverse neurological reactions 1

The European Society of Anaesthesiology recommends avoiding morphine and codeine in patients with renal insufficiency; fentanyl and methadone are relatively safe since they do not have active metabolites 3
The American College of Clinical Pharmacology suggests that fentanyl may be the preferred opioid in patients with hepatic insufficiency, although its half-life is prolonged with repeated or high doses 3
The American Society of Clinical Oncology notes that patients with a history of previous episodes of opioid-induced neurotoxicity are at higher risk of recurrence and should be monitored more closely 1

The European Society for Medical Oncology recommends monitoring the resolution of neurological symptoms after therapeutic intervention 2
The American Heart Association suggests evaluating the continued need for opioid therapy and considering alternatives for long-term pain management 5
The American Society of Clinical Oncology advises documenting the episode to prevent future exposures to the same opioid or similar doses 1